Browse SETD1B

Summary
SymbolSETD1B
NameSET domain containing 1B
Aliases KIAA1076; Set1B; KMT2G; SET domain-containing protein 1B; hSET1B; lysine N-methyltransferase 2G; Histone-lys ......
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus speckle Chromosome Note=Localizes to a largely non-overlapping set of euchromatic nuclear speckles with SETD1A, suggesting that SETD1A and SET1B each bind to a unique set of target genes.
Domain PF11764 COMPASS (Complex proteins associated with Set1p) component N
PF00076 RNA recognition motif. (a.k.a. RRM
PF00856 SET domain
Function

Histone methyltransferase that specifically methylates 'Lys-4' of histone H3, when part of the SET1 histone methyltransferase (HMT) complex, but not if the neighboring 'Lys-9' residue is already methylated. H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation. The non-overlapping localization with SETD1A suggests that SETD1A and SETD1B make non-redundant contributions to the epigenetic control of chromatin structure and gene expression. Specifically tri-methylates 'Lys-4' of histone H3 in vitro.

> Gene Ontology
 
Biological Process GO:0006479 protein methylation
GO:0008213 protein alkylation
GO:0016570 histone modification
GO:0016571 histone methylation
GO:0018022 peptidyl-lysine methylation
GO:0018205 peptidyl-lysine modification
GO:0032259 methylation
GO:0034968 histone lysine methylation
GO:0043414 macromolecule methylation
GO:0051568 histone H3-K4 methylation
Molecular Function GO:0008168 methyltransferase activity
GO:0008170 N-methyltransferase activity
GO:0008276 protein methyltransferase activity
GO:0008757 S-adenosylmethionine-dependent methyltransferase activity
GO:0016278 lysine N-methyltransferase activity
GO:0016279 protein-lysine N-methyltransferase activity
GO:0016741 transferase activity, transferring one-carbon groups
GO:0018024 histone-lysine N-methyltransferase activity
GO:0042054 histone methyltransferase activity
GO:0042800 histone methyltransferase activity (H3-K4 specific)
Cellular Component GO:0016604 nuclear body
GO:0016607 nuclear speck
GO:0034708 methyltransferase complex
GO:0035097 histone methyltransferase complex
GO:0048188 Set1C/COMPASS complex
> KEGG and Reactome Pathway
 
KEGG hsa00310 Lysine degradation
Reactome R-HSA-3247509: Chromatin modifying enzymes
R-HSA-4839726: Chromatin organization
R-HSA-3214841: PKMTs methylate histone lysines
Summary
SymbolSETD1B
NameSET domain containing 1B
Aliases KIAA1076; Set1B; KMT2G; SET domain-containing protein 1B; hSET1B; lysine N-methyltransferase 2G; Histone-lys ......
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SETD1B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between SETD1B and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28381543Breast CarcinomaInhibit immunity (T cell function)Instead, tumor-induced MDSCs showed increased SETD1B expression as compared with their cellular equivalents in tumor-free mice. Chromatin immunoprecipitation revealed that H3K4me3, the target of SETD1B, was enriched at the nos2 promoter in tumor-induced MDSCs, and inhibition or silencing of SETD1B diminished iNOS expression in tumor-induced MDSCs. Our results show how tumor cells use the SETD1B-H3K4me3 epigenetic axis to bypass a normal role for IRF8 expression in activating iNOS expression in MDSCs when they are generated under pathologic conditions.
Summary
SymbolSETD1B
NameSET domain containing 1B
Aliases KIAA1076; Set1B; KMT2G; SET domain-containing protein 1B; hSET1B; lysine N-methyltransferase 2G; Histone-lys ......
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SETD1B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSETD1B
NameSET domain containing 1B
Aliases KIAA1076; Set1B; KMT2G; SET domain-containing protein 1B; hSET1B; lysine N-methyltransferase 2G; Histone-lys ......
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SETD1B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0420.829
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3370.777
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1770.833
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.080.792
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1670.952
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.030.993
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2350.451
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2450.858
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1990.899
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6570.366
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.990.339
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0290.591
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SETD1B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.37.4-2.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.17.71.41
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.115.4-6.31
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512016.7-16.71
Summary
SymbolSETD1B
NameSET domain containing 1B
Aliases KIAA1076; Set1B; KMT2G; SET domain-containing protein 1B; hSET1B; lysine N-methyltransferase 2G; Histone-lys ......
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SETD1B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSETD1B
NameSET domain containing 1B
Aliases KIAA1076; Set1B; KMT2G; SET domain-containing protein 1B; hSET1B; lysine N-methyltransferase 2G; Histone-lys ......
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SETD1B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SETD1B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSETD1B
NameSET domain containing 1B
Aliases KIAA1076; Set1B; KMT2G; SET domain-containing protein 1B; hSET1B; lysine N-methyltransferase 2G; Histone-lys ......
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SETD1B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSETD1B
NameSET domain containing 1B
Aliases KIAA1076; Set1B; KMT2G; SET domain-containing protein 1B; hSET1B; lysine N-methyltransferase 2G; Histone-lys ......
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SETD1B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSETD1B
NameSET domain containing 1B
Aliases KIAA1076; Set1B; KMT2G; SET domain-containing protein 1B; hSET1B; lysine N-methyltransferase 2G; Histone-lys ......
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SETD1B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSETD1B
NameSET domain containing 1B
Aliases KIAA1076; Set1B; KMT2G; SET domain-containing protein 1B; hSET1B; lysine N-methyltransferase 2G; Histone-lys ......
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SETD1B collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.